Shanghai Fosun Pharmaceutical (Group) Co., Ltd.’s SAF-189s (foritinib succinate), a second-generation ALK/ROS1 inhibitor being developed as a first-line therapy, has shown efficacy superior to crizotinib (Pfizer Inc.'s Xalkori) in a Phase III trial for ALK-positive, advanced non-small cell lung cancer (NSCLC).
Interim results from the REMARK study with the oral central nervous system (CNS)-penetrating molecule, which can cross the blood-brain barrier, were presented at the 2024 World Conference on Lung Cancer...
